Integra Therapeutics
Barcelona-based biotech startup developing next-generation 'gene writing' tools (FiCAT) that combine CRISPR-Cas precision with an engineered piggyBac transposase to enable larger payloads, more stable and more precise genomic integrations. Applications include next-generation CAR-T and direct gene therapies for rare pediatric diseases; company is advancing preclinical CAR-T candidates and a gene therapy program supported by EIC funding, and pursues industry partnerships and licensing to enable scale and regulatory translation.
Finanzierungsrunden
1
Gesamtvolumen
€11.5 Mio.
Letzte Runde
Pre-Seed
Investoren
6
Finanzierung nach Stage
Finanzierungsrunden
| Stage | Betrag | Investoren | Datum |
|---|---|---|---|
| Pre-Seed | €11.5 Mio. | 08. Sept. 2025 |
